371 related articles for article (PubMed ID: 16116223)
1. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
2. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
3. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
[TBL] [Abstract][Full Text] [Related]
4. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
Lindqvist M; Persson J; Thörn K; Harandi AM
J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
6. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
[TBL] [Abstract][Full Text] [Related]
7. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.
Dwivedi V; Manickam C; Dhakal S; Binjawadagi B; Ouyang K; Hiremath J; Khatri M; Hague JG; Lee CW; Renukaradhya GJ
Vet Microbiol; 2016 Apr; 186():157-63. PubMed ID: 27016770
[TBL] [Abstract][Full Text] [Related]
9. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
11. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
12. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.
Kopecky-Bromberg SA; Fraser KA; Pica N; Carnero E; Moran TM; Franck RW; Tsuji M; Palese P
Vaccine; 2009 Jun; 27(28):3766-74. PubMed ID: 19464560
[TBL] [Abstract][Full Text] [Related]
13. α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
Chuang YH; Wang TC; Jen HY; Yu AL; Chiang BL
J Immunol; 2011 Apr; 186(8):4687-92. PubMed ID: 21383248
[TBL] [Abstract][Full Text] [Related]
14. Th17 cells contribute to nontypeable Haemophilus influenzae-specific protective immunity induced by nasal vaccination with P6 outer membrane protein and α-galactosylceramide.
Noda K; Kodama S; Umemoto S; Nomi N; Hirano T; Suzuki M
Microbiol Immunol; 2011 Aug; 55(8):574-81. PubMed ID: 21605159
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
Kayamuro H; Yoshioka Y; Abe Y; Arita S; Katayama K; Nomura T; Yoshikawa T; Kubota-Koketsu R; Ikuta K; Okamoto S; Mori Y; Kunisawa J; Kiyono H; Itoh N; Nagano K; Kamada H; Tsutsumi Y; Tsunoda S
J Virol; 2010 Dec; 84(24):12703-12. PubMed ID: 20881038
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
Kamijuku H; Nagata Y; Jiang X; Ichinohe T; Tashiro T; Mori K; Taniguchi M; Hase K; Ohno H; Shimaoka T; Yonehara S; Odagiri T; Tashiro M; Sata T; Hasegawa H; Seino KI
Mucosal Immunol; 2008 May; 1(3):208-18. PubMed ID: 19079180
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
Okazaki S; Iwasaki T; Yuba E; Watarai S
J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
[TBL] [Abstract][Full Text] [Related]
18. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
[TBL] [Abstract][Full Text] [Related]
19. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
[TBL] [Abstract][Full Text] [Related]
20. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
